Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020194346 - FUSION PROTEIN FOR CANCER THERAPY

Publication Number WO/2020/194346
Publication Date 01.10.2020
International Application No. PCT/IN2020/050272
International Filing Date 24.03.2020
IPC
C07K 14/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 47/64 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Applicants
  • COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH [IN]/[IN]
Inventors
  • THAKUR, Krishan Gopal
  • ARORA, Anjuman
  • VERMA, Dipesh
Agents
  • KOUL, Sunaina
  • SALHOTRA, Anuradha
  • DHAWAN, Ramesh Chander
  • GARG, Avi
  • P.H.D, Rangappa
  • PRASAD, Suman Lata
  • KUMARI, Sukanya
  • DEY, Sujata
  • SETHURAMAN S, Vishwas
  • WADHWA, Nisha
  • AZHAR, Tauquir
  • GARG, Rahul
Priority Data
20191101160826.03.2019IN
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) FUSION PROTEIN FOR CANCER THERAPY
(FR) PROTÉINE DE FUSION POUR LA THÉRAPIE DU CANCER
Abstract
(EN)
The present invention discloses a fusion protein for cancer therapy. The invention discloses a fusion protein economically produced using Escherichia coli as an expression host. In the present invention, the target specific cell penetration is achieved by a fusion of CPPs. The present invention also discloses the production and purification of the fusion proteins for downstream applications.
(FR)
La présente invention concerne une protéine de fusion pour la thérapie du cancer. L'invention concerne une protéine de fusion produite de manière économique à l'aide d'Escherichia coli en tant qu'hôte d'expression. Dans la présente invention, la pénétration cellulaire spécifique cible est obtenue par une fusion de CPP. La présente invention concerne également la production et la purification des protéines de fusion pour des applications en aval.
Latest bibliographic data on file with the International Bureau